KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $81.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $81.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $81.0 million, a N/A change, with the full-year FY2023 number at $81.0 million, down 91.75% from a year prior.
  • Long-Term Deferred Tax was $81.0 million for Q3 2024 at Moderna, roughly flat from $81.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $1.5 billion in Q2 2023 to a low of $50.0 million in Q1 2021.
  • A 4-year average of $485.5 million and a median of $203.5 million in 2021 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 1089.39% in 2022, then plummeted 94.53% in 2024.
  • Moderna's Long-Term Deferred Tax stood at $326.0 million in 2021, then surged by 201.23% to $982.0 million in 2022, then plummeted by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
  • Per Business Quant, the three most recent readings for MRNA's Long-Term Deferred Tax are $81.0 million (Q3 2024), $81.0 million (Q2 2024), and $81.0 million (Q1 2024).